当前位置：首页 SCI 期刊医学 Cancer Investigation(非官网)

Cancer InvestigationSCIE

国际简称：CANCER INVEST 参考译名：癌症调查

中科院分区
4区
CiteScore分区
Q3
JCR分区
Q3

基本信息：: ISSN：0735-7907; E-ISSN：1532-4192; 是否OA：未开放; 是否预警：否; TOP期刊：否

出版信息：: 出版地区：UNITED STATES; 出版商：Informa Healthcare; 出版语言：English; 出版周期：Bimonthly; 出版年份：1983; 研究方向：医学-肿瘤学

评价信息：: 影响因子：1.8; H-index：77; CiteScore指数：3.8; SJR指数：0.604; SNIP指数：0.472

发文数据：: Gold OA文章占比：7.62%; 研究类文章占比：83.02%; 年发文量：53; 自引率：0.0416...; 开源占比：0.0535; 出版撤稿占比：0; 出版国人文章占比：0.16; OA被引用占比：0.0149...

投稿咨询加急见刊

英文简介期刊介绍 CiteScore数据中科院SCI分区 JCR分区发文数据常见问题

英文简介Cancer Investigation期刊介绍

Cancer Investigation is one of the most highly regarded and recognized journals in the field of basic and clinical oncology. It is designed to give physicians a comprehensive resource on the current state of progress in the cancer field as well as a broad background of reliable information necessary for effective decision making. In addition to presenting original papers of fundamental significance, it also publishes reviews, essays, specialized presentations of controversies, considerations of new technologies and their applications to specific laboratory problems, discussions of public issues, miniseries on major topics, new and experimental drugs and therapies, and an innovative letters to the editor section. One of the unique features of the journal is its departmentalized editorial sections reporting on more than 30 subject categories covering the broad spectrum of specialized areas that together comprise the field of oncology. Edited by leading physicians and research scientists, these sections make Cancer Investigation the prime resource for clinicians seeking to make sense of the sometimes-overwhelming amount of information available throughout the field. In addition to its peer-reviewed clinical research, the journal also features translational studies that bridge the gap between the laboratory and the clinic.

期刊简介Cancer Investigation期刊介绍

《Cancer Investigation》自1983出版以来，是一本医学优秀杂志。致力于发表原创科学研究结果，并为医学各个领域的原创研究提供一个展示平台，以促进医学领域的的进步。该刊鼓励先进的、清晰的阐述，从广泛的视角提供当前感兴趣的研究主题的新见解，或审查多年来某个重要领域的所有重要发展。该期刊特色在于及时报道医学领域的最新进展和新发现新突破等。该刊近一年未被列入预警期刊名单，目前已被权威数据库SCIE收录，得到了广泛的认可。

该期刊投稿重要关注点：

预计审稿时间：约8.5月
医学
ONCOLOGY
SCIE
中科院4区
非预警

Cite Score数据（2024年最新版）Cancer Investigation Cite Score数据

CiteScore：3.8
SJR：0.604
SNIP：0.472

学科类别	分区	排名	百分位
大类：Medicine 小类：Oncology	Q3	217 / 404	46%
大类：Medicine 小类：Cancer Research	Q3	160 / 230	30%

CiteScore 是由Elsevier(爱思唯尔)推出的另一种评价期刊影响力的文献计量指标。反映出一家期刊近期发表论文的年篇均引用次数。CiteScore以Scopus数据库中收集的引文为基础，针对的是前四年发表的论文的引文。CiteScore的意义在于，它可以为学术界提供一种新的、更全面、更客观地评价期刊影响力的方法，而不仅仅是通过影响因子(IF)这一单一指标来评价。

历年Cite Score趋势图

中科院SCI分区Cancer Investigation 中科院分区

中科院 2023年12月升级版 综述期刊：否 Top期刊：否

大类学科	分区	小类学科	分区
医学	4区	ONCOLOGY 肿瘤学	4区

中科院分区表 是以客观数据为基础，运用科学计量学方法对国际、国内学术期刊依据影响力进行等级划分的期刊评价标准。它为我国科研、教育机构的管理人员、科研工作者提供了一份评价国际学术期刊影响力的参考数据，得到了全国各地高校、科研机构的广泛认可。

中科院分区表 将所有期刊按照一定指标划分为1区、2区、3区、4区四个层次，类似于“优、良、及格”等。最开始，这个分区只是为了方便图书管理及图书情报领域的研究和期刊评估。之后中科院分区逐步发展成为了一种评价学术期刊质量的重要工具。

历年中科院分区趋势图

JCR分区Cancer Investigation JCR分区

2023-2024 年最新版

按JIF指标学科分区	收录子集	分区	排名	百分位
学科：ONCOLOGY	SCIE	Q3	241 / 322	25.3%

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：ONCOLOGY	SCIE	Q4	246 / 322	23.76%

JCR分区的优势在于它可以帮助读者对学术文献质量进行评估。不同学科的文章引用量可能存在较大的差异，此时单独依靠影响因子(IF)评价期刊的质量可能是存在一定问题的。因此，JCR将期刊按照学科门类和影响因子分为不同的分区，这样读者可以根据自己的研究领域和需求选择合适的期刊。

历年影响因子趋势图

发文数据

2023-2024 年国家/地区发文量统计

国家/地区数量
USA52
CHINA MAINLAND35
Japan18
India11
Italy11
Iran9
France8
GERMANY (FED REP GER)5
Australia4
Brazil4

本刊中国学者近年发表论文

1、Trends and Projections of Stomach Cancer Incidence in Hong Kong: A Population-Based Study
Author: Yang, Liping; Sun, Haifeng; Bai, Yan; Sun, Shengzhi; Wu, Xiaoming; Gan, Zhenhai; Du, Jianqiang; Du, Jianfei

Journal: CANCER INVESTIGATION. 2023; Vol. 41, Issue 4, pp. 319-329. DOI: 10.1080/07357907.2022.2126982
2、Tumoral Overexpression of Hepcidin is Associated with Poor Prognosis of Patients with Clear Cell Renal Cell Carcinoma
Author: Qiu, Huizhu; Gu, Guojian; Zuo, Erdong; Cheng, Xu

Journal: CANCER INVESTIGATION. 2023; Vol. 41, Issue 1, pp. 84-92. DOI: 10.1080/07357907.2022.2133775
3、The Prognostic Value of ADAMTS8 and Its Role as a Tumor Suppressor in Breast Cancer
Author: Zhang, Qia; Kanyomse, Quist; Luo, Chenghao; Mo, Qingfan; Zhao, XunPing; Wang, Long; Peng, Weiyan; Ren, Guosheng

Journal: CANCER INVESTIGATION. 2023; Vol. 41, Issue 2, pp. 119-132. DOI: 10.1080/07357907.2022.2128367
4、A DNA Damage Response Related Signature to Predict Prognosis in Patients with Acute Myeloid Leukemia
Author: Wang, Jun; Wu, Jiafei; Wang, Yijing; Wang, Yu; Jiang, Chuanyan; Zou, Mengying; Jin, Xiaokang; Sun, Xiaoran; Zhang, Yu; Ma, Sijia; Wang, Guoqiang; Zhu, Xin; Lu, Huafei; Xu, Chunwei; Wang, Wenxian; Li, Leo; Han, Yusheng; Cai, Shangli; Li, Hui

Journal: CANCER INVESTIGATION. 2023; Vol. 41, Issue 3, pp. 271-283. DOI: 10.1080/07357907.2023.2167209
5、Efficacy and Safety of Bevacizumab for Treating Glioblastoma: A Systematic Review and Meta-Analysis of Phase II and III Randomized Controlled Trials
Author: Xie, Xiaohong; Bao, Shangyi; Zhao, Hong; Li, Liuying; Fu, Xiaojun

Journal: CANCER INVESTIGATION. 2023; Vol. 41, Issue 3, pp. 305-317. DOI: 10.1080/07357907.2023.2174261
6、Poorly Controlled Diabetes Mellitus Increases the Risk of Deaths and Castration-Resistance in Locally Advanced Prostate Cancer Patients
Author: Ma, Cheng; Cui, Di; Han, Bangmin; Ding, Mao; Zhang, Jiahao; Liu, Shiyun; Gao, Yingli; Xia, Shujie

Journal: CANCER INVESTIGATION. 2023; Vol. 41, Issue 4, pp. 345-353. DOI: 10.1080/07357907.2023.2171050
7、Identification and Validation of Molecular Subtype and Prognostic Signature for Bladder Cancer Based on Neutrophil Extracellular Traps
Author: Tu, Yaofen; Mao, Zujie

Journal: CANCER INVESTIGATION. 2023; Vol. 41, Issue 4, pp. 354-368. DOI: 10.1080/07357907.2023.2179063
8、Bioinformatics Identification and Validation of Aging-Related Molecular Subtype and Prognostic Signature in Sarcoma
Author: Hong, Xu; Liu, Hui; Chen, Chu; Lai, Tian; Lin, Jingui

Journal: CANCER INVESTIGATION. 2023; Vol. , Issue , pp. -. DOI: 10.1080/07357907.2023.2209638